University City Sustainability Plan, Fall 2020 & Spring 2021

University City Sustainability Plan, Sustainability Exchange, Washington University in St. Louis, Fall 2020 & Spring 202

Molecular Investigations of PenA-mediated β-lactam Resistance in Burkholderia pseudomallei

Burkholderia pseudomallei is the etiological agent of melioidosis. Because of the bacterium’s intrinsic resistance and propensity to establish latent infections, melioidosis therapy is complicated and prolonged. Newer generation β-lactams, specifically ceftazidime, are used for acute phase therapy, but resistance to this cephalosporin has been observed. The chromosomally encoded penA gene encodes a putative twin arginine translocase (TAT)-secreted β-lactamase, and penA mutations have been implicated in ceftazidime resistance in clinical isolates. However, the role of PenA in resistance has not yet been systematically studied in isogenetic B. pseudomallei mutant backgrounds. We investigated the effects of penA deletion, point mutations, and up-regulation, as well as tat operon deletion and PenA TAT-signal sequence mutations. These experiments were made possible by employing a B. pseudomallei strain that is excluded from Select Agent regulations. Deletion of penA significantly (>4-fold) reduced the susceptibility to six of the nine β-lactams tested and ≥16-fold for ampicillin, amoxicillin, and carbenicillin. Overexpression of penA by single-copy, chromosomal expression of the gene under control of the inducible Ptac promoter, increased resistance levels for all β-lactams tested 2- to 10-fold. Recreation of the C69Y and P167S PenA amino acid substitutions previously observed in resistant clinical isolates increased resistance to ceftazidime by ≥85- and 5- to 8-fold, respectively. Similarly, a S72F substitution resulted in a 4-fold increase in resistance to amoxicillin and clavulanic acid. Susceptibility assays with PenA TAT-signal sequence and ΔtatABC mutants, as well as Western blot analysis, confirmed that PenA is a TAT secreted enzyme and not periplasmic but associated with the spheroplastic cell fraction. Lastly, we determined that two LysR-family regulators encoded by genes adjacent to penA do not play a role in transcriptional regulation of penA expression

An improved selective culture medium enhances the isolation of Burkholderia pseudomallei from contaminated specimens.

Burkholderia pseudomallei is a Gram-negative environmental bacterium found in tropical climates that causes melioidosis. Culture remains the diagnostic gold standard, but isolation of B. pseudomallei from heavily contaminated sites, such as fecal specimens, can be difficult. We recently reported that B. pseudomallei is capable of infecting the gastrointestinal tract of mice and suggested that the same may be true in humans. Thus, there is a strong need for new culture techniques to allow for efficient detection of B. pseudomallei in fecal and other specimens. We found that the addition of norfloxacin, ampicillin, and polymyxin B to Ashdown's medium (NAP-A) resulted in increased specificity without affecting the growth of 25 B. pseudomallei strains. Furthermore, recovery of B. pseudomallei from human clinical specimens was not affected by the three additional antibiotics. Therefore, we conclude that NAP-A medium provides a new tool for more sensitive isolation of B. pseudomallei from heavily contaminated sites

Methods for genetic manipulation of Burkholderia gladioli pathovar cocovenenans

<p>Abstract</p> <p>Background</p> <p><it>Burkholderia gladioli </it>pathovar <it>cocovenenans </it>(BGC) is responsible for sporadic food-poisoning outbreaks with high morbidity and mortality in Asian countries. Little is known about the regulation of virulence factor and toxin production in BGC, and studies in this bacterium have been hampered by lack of genetic tools.</p> <p>Findings</p> <p>Establishment of a comprehensive antibiotic susceptibility profile showed that BGC strain ATCC33664 is susceptible to a number of antibiotics including aminoglycosides, carbapenems, fluoroquinolones, tetracyclines and trimethoprim. In this study, we established that gentamicin, kanamycin and trimethoprim are good selection markers for use in BGC. Using a 10 min method for preparation of electrocompetent cells, the bacterium could be transformed by electroporation at high frequencies with replicative plasmids containing the pRO1600-derived origin of replication. These plasmids exhibited a copy number of > 100 in BGC. When co-conjugated with a transposase expressing helper plasmid, mini-Tn<it>7 </it>vectors inserted site- and orientation-specifically at a single <it>glmS</it>-associated insertion site in the BGC genome. Lastly, a <it>Himar1 </it>transposon was used for random transposon mutagenesis of BGC.</p> <p>Conclusions</p> <p>A series of genetic tools previously developed for other Gram-negative bacteria was adapted for use in BGC. These tools now facilitate genetic studies of this pathogen and allow establishment of toxin biosynthetic pathways and their genetic regulation.</p

Identification of genes required for soil survival in Burkholderia thailandensis by transposon-directed insertion site sequencing.

Transposon-directed insertion site sequencing was used to identify genes required by Burkholderia thailandensis to survive in plant/soil microcosms. A total of 1,153 genetic loci fulfilled the criteria as being likely to encode survival characteristics. Of these, 203 (17.6 %) were associated with uptake and transport systems; 463 loci (40.1 %) coded for enzymatic properties, 99 of these (21.4 %) had reduction/oxidation functions; 117 (10.1 %) were gene regulation or sensory loci; 61 (5.3 %) encoded structural proteins found in the cell envelope or with enzymatic activities related to it, distinct from these, 46 (4.0 %) were involved in chemotaxis and flagellum, or pilus synthesis; 39 (3.4 %) were transposase enzymes or were bacteriophage-derived; and 30 (2.6 %) were involved in the production of antibiotics or siderophores. Two hundred and twenty genes (19.1 %) encoded hypothetical proteins or those of unknown function. Given the importance of motility and pilus formation in microcosm persistence the nature of the colonization of the rhizosphere was examined by confocal microscopy. Wild type B. thailandensis expressing red fluorescent protein was inoculated into microcosms. Even though the roots had been washed, the bacteria were still present but they were motile with no attachment having taken place, perhaps being retained in a biofilm

Characterization of Ceftazidime Resistance Mechanisms in Clinical Isolates of Burkholderia pseudomallei from Australia

Burkholderia pseudomallei is a Gram-negative bacterium that causes the serious human disease, melioidosis. There is no vaccine against melioidosis and it can be fatal if not treated with a specific antibiotic regimen, which typically includes the third-generation cephalosporin, ceftazidime (CAZ). There have been several resistance mechanisms described for B. pseudomallei, of which the best described are amino acid changes that alter substrate specificity in the highly conserved class A β-lactamase, PenA. In the current study, we sequenced penA from isolates sequentially derived from two melioidosis patients with wild-type (1.5 µg/mL) and, subsequently, resistant (16 or ≥256 µg/mL) CAZ phenotypes. We identified two single-nucleotide polymorphisms (SNPs) that directly increased CAZ hydrolysis. One SNP caused an amino acid substitution (C69Y) near the active site of PenA, whereas a second novel SNP was found within the penA promoter region. In both instances, the CAZ resistance phenotype corresponded directly with the SNP genotype. Interestingly, these SNPs appeared after infection and under selection from CAZ chemotherapy. Through heterologous cloning and expression, and subsequent allelic exchange in the native bacterium, we confirmed the role of penA in generating both low-level and high-level CAZ resistance in these clinical isolates. Similar to previous studies, the amino acid substitution altered substrate specificity to other β-lactams, suggesting a potential fitness cost associated with this mutation, a finding that could be exploited to improve therapeutic outcomes in patients harboring CAZ resistant B. pseudomallei. Our study is the first to functionally characterize CAZ resistance in clinical isolates of B. pseudomallei and to provide proven and clinically relevant signatures for monitoring the development of antibiotic resistance in this important pathogen

Evolution of Burkholderia pseudomallei in Recurrent Melioidosis

Burkholderia pseudomallei, the etiologic agent of human melioidosis, is capable of causing severe acute infection with overwhelming septicemia leading to death. A high rate of recurrent disease occurs in adult patients, most often due to recrudescence of the initial infecting strain. Pathogen persistence and evolution during such relapsing infections are not well understood. Bacterial cells present in the primary inoculum and in late infections may differ greatly, as has been observed in chronic disease, or they may be genetically similar. To test these alternative models, we conducted whole-genome comparisons of clonal primary and relapse B. pseudomallei isolates recovered six months to six years apart from four adult Thai patients. We found differences within each of the four pairs, and some, including a 330 Kb deletion, affected substantial portions of the genome. Many of the changes were associated with increased antibiotic resistance. We also found evidence of positive selection for deleterious mutations in a TetR family transcriptional regulator from a set of 107 additional B. pseudomallei strains. As part of the study, we sequenced to base-pair accuracy the genome of B. pseudomallei strain 1026b, the model used for genetic studies of B. pseudomallei pathogenesis and antibiotic resistance. Our findings provide new insights into pathogen evolution during long-term infections and have important implications for the development of intervention strategies to combat recurrent melioidosis

β-lactam resistance mechanisms in Burkholderia pseudomallei and the tools used for their elucidation

2011 Summer.Includes bibliographical references.A state of fear can arise from being unable to stop an impending threat. This can be the case of those infected with Burkholderia pseudomallei, the etiological agent of melioidosis. The 9-54% mortality rate, despite proper treatment, can be partially attributed to a combination of high levels of intrinsic and acquired antibiotic resistance causing treatment failure, unreliable/time-consuming diagnostics and a plethora of virulence factors. Even into the late 1980's, mortality was upwards of 80%. Its success as both a soil microbe and a highly antibiotic-resistant broad-host pathogen are in part due to its large genome and extensive metabolic capabilities. For these reasons and others, the Centers for Disease Control named B. pseudomallei a potential biothreat agent and a Category B select agent. The above mentioned attributes of B. pseudomallei make the bacterium's study both challenging and necessary. CDC select agent guidelines complicate the use of many effective molecular tools, making the job of elucidating the attributes of specific genetic elements difficult. Thus, the construction of new systems for genetic manipulation was required. Chapters 3 and 6 and parts of chapter 5 describe novel tools that have since been successfully used to genetically manipulate B. pseudomallei in an efficient and select-agent compliant fashion. Chapter 3 details construction of a transposon Himar1-based random mutagenesis system. Such systems have proven indispensable tools for the study of bacteria as they facilitate identification of metabolic pathways, virulence factors, antibiotic resistance mechanisms and other cellular processes. Chapter 6 describes improvements to existing tools, a new Escherichia coli mobilizer strain (RHO3) and an improved Tn7 transposase expression vector (pTNS3). RHO3 is the most versatile E. coli mobilizer strain engineered to date. It combines the plasmid mobilization efficiency of the widely used SM10 mobilizer strain with engineered kanamycin susceptibility and metabolic counterselection on rich media. The pTNS3 helper plasmid was engineered to express the Tn7 site-specific transposition pathway more efficiently by inclusion of the strong, broad-host-range P1 integron promoter in addition to the E. coli lactose-tryptophan Ptac hybrid promoter. Chapter 5 describes the application of a combination of the mini-Tn7-based single-copy chromosomal integration and expression system with the site-specific Cre recombinase system for temporary expression of a rescue gene aiding in characterization of essential genes. The work of defining novel resistance mechanisms is necessary to discover why recommended treatment regimens can fail. Use of ceftazidime in initial treatment of melioidosis halved the mortality rate. Because it is one of the few effective treatment options, resistance to this β-lactam is of great interest. Molecular definition of such mechanisms (chapters 4 and 5) could improve diagnostic capabilities, both clinically and in the case of a bioterrorism event. Chapter 4 describes the novel finding that the chromosomally encoded PenA β-lactamase is secreted via the twin arginine translocase system and that penA neighboring regulatory genes are most likely not involved in the regulation of expression of this gene. The work described in this chapter also established that PenA is the major B. pseudomallei β-lactam resistance mechanism and defined several mutations leading to ceftazidime and amoxicillin + clavulanic acid resistance. These findings form the basis for development of diagnostic tools for the detection of mutations causing high level resistance to clinically significant antibiotics which will allow initiation (biodefense) or redirection (clinical melioidosis) of proper antibiotic therapy. Work described in Chapter 5 defines deletion of the penicillin-binding protein 3 BPSS1219 as a novel ceftazidime resistance mechanism observed in B. pseudomallei strains isolated from patients that failed ceftazidime therapy. Through this body of work, I hope to have shed light on aspects of the biology of B. pseudomallei, novel genetic tools for its manipulation and novel mechanisms of β-lactam resistance